PlainRecalls
FDA Devices Moderate Class II Ongoing

SpaceOAR Vue System, UPN SV-1010 and SV-2101. Used to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer to reduce the radiation dose delivered to the anterior rectum.

Reported: May 4, 2022 Initiated: February 24, 2022 #Z-1003-2022

Product Description

SpaceOAR Vue System, UPN SV-1010 and SV-2101. Used to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer to reduce the radiation dose delivered to the anterior rectum.

Reason for Recall

Users need to be aware that embolism is a possible adverse event associated with hydrogel misplacements. Updated IFU provides new procedural instructions, warnings and precautions that describe steps to verify correct placement of the hydrogel following implantation, as well as technique recommendations for the proper placement of SpaceOAR and SpaceOAR Vue.

Details

Units Affected
23,368 units
Distribution
Worldwide - US Nationwide distribution.
Location
Marlborough, MA

Frequently Asked Questions

What product was recalled?
SpaceOAR Vue System, UPN SV-1010 and SV-2101. Used to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer to reduce the radiation dose delivered to the anterior rectum.. Recalled by Boston Scientific Corporation. Units affected: 23,368 units.
Why was this product recalled?
Users need to be aware that embolism is a possible adverse event associated with hydrogel misplacements. Updated IFU provides new procedural instructions, warnings and precautions that describe steps to verify correct placement of the hydrogel following implantation, as well as technique recommendations for the proper placement of SpaceOAR and SpaceOAR Vue.
Which agency issued this recall?
This recall was issued by the FDA Devices on May 4, 2022. Severity: Moderate. Recall number: Z-1003-2022.